|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Capitalization1 |
87 528 | 94 860 | 132 331 | 137 952 | - | - |
| Entreprise Value (EV)1 |
102 011 | 109 142 | 144 340 | 151 130 | 149 231 | 146 526 |
| P/E ratio |
29,2x | 44,0x | 97,9x | 47,8x | 32,5x | 24,1x |
| Yield |
4,05% | 3,74% | 2,78% | 2,68% | 2,71% | 2,77% |
| Capitalization / Revenue |
3,90x | 4,29x | 5,43x | 5,17x | 4,56x | 4,05x |
| EV / Revenue |
4,54x | 4,94x | 5,92x | 5,66x | 4,93x | 4,30x |
| EV / EBITDA |
15,2x | 15,3x | 21,6x | 19,2x | 14,9x | 11,9x |
| Price to Book |
5,85x | 7,61x | 10,00x | 10,5x | 9,65x | 8,09x |
| Nbr of stocks (in thousands) |
1 265 982 | 1 266 812 | 1 311 913 | 1 312 296 | - | - |
| Reference price (USD) |
69,1 | 74,9 | 101 | 105 | 105 | 105 |
| Last update |
02/02/2018 | 02/14/2019 | 02/14/2020 | 10/23/2020 | 10/23/2020 | 10/23/2020 |
|
1 USD in Million Estimates
|
|
| Income Statement Evolution | |
|
|
|
| Annual Income Statement Data |
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net sales1 |
22 465 | 22 090 | 24 384 | 26 703 | 30 264 | 34 088 |
| EBITDA1 |
6 713 | 7 140 | 6 686 | 7 857 | 10 001 | 12 289 |
| Operating profit (EBIT)1 |
6 855 | 5 672 | 6 436 | 7 447 | 9 185 | 11 155 |
| Operating Margin |
30,5% | 25,7% | 26,4% | 27,9% | 30,3% | 32,7% |
| Pre-Tax Profit (EBT)1 |
2 227 | 1 993 | 1 548 | 3 952 | 6 195 | 8 772 |
| Net income1 |
3 001 | 2 155 | 1 335 | 3 074 | 4 530 | 6 132 |
| Net margin |
13,4% | 9,76% | 5,47% | 11,5% | 15,0% | 18,0% |
| EPS2 |
2,37 | 1,70 | 1,03 | 2,20 | 3,23 | 4,36 |
| Dividend per Share2 |
2,80 | 2,80 | 2,80 | 2,82 | 2,85 | 2,91 |
| Last update |
02/02/2018 | 02/14/2019 | 02/14/2020 | 10/23/2020 | 10/23/2020 | 10/23/2020 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net Debt1 |
14 483 | 14 282 | 12 009 | 13 178 | 11 278 | 8 573 |
| Net Cash position1 |
- | - | - | - | - | - |
| Leverage (Debt / EBITDA) |
2,16x | 2,00x | 1,80x | 1,68x | 1,13x | 0,70x |
| Free Cash Flow1 |
2 252 | 1 575 | 1 990 | 3 513 | 5 998 | 7 863 |
| ROE (Net Profit / Equities) |
36,4% | 32,0% | 35,6% | 41,4% | 51,7% | 58,1% |
| Shareholders' equity1 |
8 250 | 6 742 | 3 752 | 7 416 | 8 768 | 10 548 |
| ROA (Net Profit / Asset) |
4,77% | 7,07% | 2,19% | 7,10% | 9,00% | 11,2% |
| Assets1 |
62 940 | 30 480 | 61 015 | 43 295 | 50 338 | 54 992 |
| Book Value Per Share2 |
11,8 | 9,84 | 10,1 | 10,0 | 10,9 | 13,0 |
| Cash Flow per Share2 |
2,82 | 2,07 | 2,28 | 3,57 | 5,10 | 6,60 |
| Capex1 |
1 326 | 1 043 | 979 | 1 147 | 1 233 | 1 351 |
| Capex / Sales |
5,90% | 4,72% | 4,01% | 4,30% | 4,07% | 3,96% |
| Last update |
02/02/2018 | 02/14/2019 | 02/14/2020 | 10/19/2020 | 10/19/2020 | 10/19/2020 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
|
Financial data source
© 2020 S&P Global Market Intelligence
|
|
|
AstraZeneca : says its Oxford vaccine deal allows it to add up to 20% of manufacturing costs |
Capitalization (GBP) 105 994 170 293 Capitalization (USD) 137 968 331 003 Net sales (USD) 24 384 000 000 Number of employees 70 600 Sales / Employee (USD) 345 382 Free-Float capitalization (GBP) 101 488 528 113 Free-Float capitalization (USD) 132 103 518 533 Avg. Exchange 20 sessions (USD) 10 720 471 941 Average Daily Capital Traded 10,11%
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Evolution Valeur d'Entreprise / EBITDA
|
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
